1. Using Split Luminescent Biosensors for SARS‐CoV‐2 Antibody Detection in Serum, Plasma, and Blood Samples
- Author
-
Susanna K, Elledge, Ian, Eigl, Maira, Phelps, Khayla, McClinton, Xin X, Zhou, Kevin K, Leung, Cristina M, Tato, and James A, Wells
- Subjects
General Immunology and Microbiology ,Clinical Laboratory Techniques ,SARS-CoV-2 ,General Neuroscience ,COVID-19 ,Health Informatics ,Biosensing Techniques ,Nucleocapsid Proteins ,Antibodies, Viral ,Sensitivity and Specificity ,General Biochemistry, Genetics and Molecular Biology ,Medical Laboratory Technology ,Humans ,General Pharmacology, Toxicology and Pharmaceutics ,Luciferases ,Pandemics - Abstract
Antibody detection assays are essential for evaluating immunity of individuals against a given virus, and this has been particularly relevant during the COVID-19 pandemic. Current serology assays either require a laboratory setting and take1 hr (i.e., enzyme-linked immunosorbent assay [ELISA]) or are rapid but only qualitative in nature and cannot accurately track antibody levels over time (i.e., lateral flow assay [LFA]). Therefore, there is a need for development of a rapid and simple but also quantitative assay that can evaluate antibody levels in patients accurately over time. We have developed an assay that uses a split nanoluciferase fused to the spike or nucleocapsid proteins of the SARS-CoV-2 virus to enable luminescent-based detection of spike- or nucleocapsid-binding antibodies in serum, plasma, and whole blood samples. The resulting approach is simple, rapid, and quantitative and is highly amenable to low-/medium-throughput scale using plate-based assays, high-throughput scale using robotics, and point-of-care applications. In this article, we describe how to perform the assay in a laboratory setting using a plate reader or liquid-handling robotics and in a point-of-care setting using a handheld, battery-powered luminometer. Together, these assays allow antibody detection to be easily performed in multiple settings by simplifying and reducing assay time in a laboratory or clinical environment and by allowing for antibody detection in point-of-care, nonlaboratory settings. © 2022 Wiley Periodicals LLC. Basic Protocol: SARS-CoV-2 antibody detection using the split-luciferase assay on a medium-throughput scale with a laboratory luminometer Alternate Protocol 1: High-throughput-based protocol for SARS-CoV-2 antibody detection using a robotic platform Alternate Protocol 2: Point-of-care-based protocol for SARS-CoV-2 antibody detection using a handheld luminometer Support Protocol: Determining positive/negative cutoffs for test samples and standardizing the assay between days.
- Published
- 2022